These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707 [TBL] [Abstract][Full Text] [Related]
6. [Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?]. Chapet O; Quero L; Azria D; Bossi A; Hennequin C; Paparel P Cancer Radiother; 2009 Sep; 13(5):416-22. PubMed ID: 19167919 [TBL] [Abstract][Full Text] [Related]
7. Pelvic lymph node irradiation for prostate cancer: who, why, and when? Wang D; Lawton C Semin Radiat Oncol; 2008 Jan; 18(1):35-40. PubMed ID: 18082586 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T; Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219 [TBL] [Abstract][Full Text] [Related]
9. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815 [TBL] [Abstract][Full Text] [Related]
10. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Kuban DA; Tucker SL; Dong L; Starkschall G; Huang EH; Cheung MR; Lee AK; Pollack A Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):67-74. PubMed ID: 17765406 [TBL] [Abstract][Full Text] [Related]
11. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. Granfors T; Modig H; Damber JE; Tomic R J Urol; 2006 Aug; 176(2):544-7. PubMed ID: 16813885 [TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Berglund RK; Jones JS; Ulchaker JC; Fergany A; Gill I; Kaouk J; Klein EA Urology; 2006 Jun; 67(6):1253-6. PubMed ID: 16678888 [TBL] [Abstract][Full Text] [Related]
13. Clinical strategies for improving the radiotherapeutic management of prostate cancer. Chuba PJ; Forman JD; Ben-Josef E; Hart KH; Porter AT Anticancer Res; 1997; 17(3A):1449-54. PubMed ID: 9179182 [TBL] [Abstract][Full Text] [Related]
14. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480 [TBL] [Abstract][Full Text] [Related]
15. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Shih HA; Harisinghani M; Zietman AL; Wolfgang JA; Saksena M; Weissleder R Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1262-9. PubMed ID: 16253781 [TBL] [Abstract][Full Text] [Related]
16. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Vargas CE; Demanes J; Boike TP; Barnaba MC; Skoolisariyaporn P; Schour L; Gustafson GS; Gonzalez J; Martinez AA Am J Clin Oncol; 2006 Oct; 29(5):451-7. PubMed ID: 17023778 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [TBL] [Abstract][Full Text] [Related]
18. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
19. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
20. [Preliminary results of radical surgery and radiotherapy of locally advanced prostate cancer (basal PSA >50 ng/ml)]. Kaprin AD; Khmelevskiĭ EV; Fadeev AV Vopr Onkol; 2007; 53(4):479-81. PubMed ID: 17969415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]